About Caelum Biosciences
Caelum Biosciences is a Healthcare company based in New York (United States) founded in 2017 by Michael Spector, and was acquired by Astrazeneca in September 2021. Chimeric monoclonal antibodies for AL Amyloidosis treatment are developed. Caelum Biosciences has raised $9.91 million across 1 funding round from investors including Astrazeneca. Its chief executive, as recorded, is Michael Spector. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Caelum Biosciences was founded in 2017 as a clinical-stage biotechnology company focused on rare diseases. Operations center on the development of CAEL-101, a chimeric fibril-reactive monoclonal antibody in Phase 1a trials for AL Amyloidosis patients. Two Orphan Drug Designations have been granted for CAEL-101, covering therapeutic and radio-imaging uses. The company is based in New York, United States, and operates as part of Fortress Biotech.
- Headquarters New York, United States
- Founders Michael Spector
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website caelumbio.com
- Social X
- Acquired by Astrazeneca (Sep 2021)
- Total Equity Funding$9.91M (USD)
in 1 rounds
- Latest Funding Round$9.91M (USD), Series A
Sep 2017
- Investors
- Acquired byAstrazeneca
(Sep 2021)
Funding Insights of Caelum Biosciences
Caelum Biosciences has successfully raised a total of $9.91M through 1 strategic funding round. The most recent funding activity was a Series A round of $9.91 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.91M
- Total Rounds 1
- Last Round Series A — $9.91M
- First Round $9.91M
(Sep 2017)
All 1 funding rounds of Caelum Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $9.91M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Caelum Biosciences
Caelum Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Astrazeneca.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Caelum Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Caelum Biosciences
1 people are tracked at Caelum Biosciences (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Spector | Co-Founder & CEO | Leadership |
Complete people profiles for Caelum Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Caelum Biosciences
3 dated milestones of Caelum Biosciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Caelum Biosciences is founded.
- Funding First funding round of $9.9M.
- Exit Acquired by Astrazeneca.
Competitors of Caelum Biosciences
Caelum Biosciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Caelum Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Caelum Biosciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Caelum Biosciences
Complete news archive for Caelum Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caelum Biosciences
Caelum Biosciences was founded in 2017.
Caelum Biosciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Michael Spector is the CEO of Caelum Biosciences, as recorded in our data. They have also founded this company.
Caelum Biosciences is a funded company, having raised a total of $9.91M across 1 funding round to date. The company's 1st funding round was a Series A of $9.91M, raised on Sep 2017.
Caelum Biosciences was founded in 2017 as a clinical-stage biotechnology company focused on rare diseases. Operations center on the development of CAEL-101, a chimeric fibril-reactive monoclonal antibody in Phase 1a trials for AL Amyloidosis patients. Two Orphan Drug Designations have been granted for CAEL-101, covering therapeutic and radio-imaging uses. The company is based in New York, United States, and operates as part of Fortress Biotech.
Caelum Biosciences has 1 investor. Key investors include Astrazeneca.
Yes. Caelum Biosciences was acquired by Astrazeneca in September 2021.